While the primary endpoint of the study is Xgeva’s safety profile, secondary endpoints include time to disease progression and the proportion of patients without any surgery at six months. Amgen said ...

Xgeva (denosumab) is a prescription drug used to treat certain bone conditions and prevent bone complications in people with cancer. Xgeva’s cost may depend on factors such as your dosage and whether ...

Xgeva (denosumab) is a prescription drug that’s used to treat some kinds of cancer. Xgeva comes as a solution inside prefilled, disposable pens that’s injected under the skin. It’s usually given once ...

Expanding across indications Xgeva and Prolia are different doses of the drug denosumab. They work by binding with a protein that's a key to producing osteoclasts, which are the cells responsible for ...

"We now finally have evidence that bone-targeted treatment is not only successful in treating bony metastases and preventing treatment-induced bone loss," said Michael Gnant. A follow-up analysis of ...

The approval is based on data from the pivotal Phase 3 '482 study, the largest international multiple myeloma clinical trial ever conducted. Amgen announced that the Food and Drug Administration (FDA) ...

Amgen wants to extend use of bone cancer drug Xgeva (denosumab) into the prevention setting, but analysts, not to mention the FDA’s own advisors, are not optimistic about its chances of securing the ...

Amgen (Nasdaq: AMGN) today announced top-line results from a Phase 3 trial evaluating XGEVA(TM) (denosumab) versus placebo in 1,432 men with castrate-resistant prostate cancer. The trial, known as the ...

XGEVA (denosumab) 120mg/1.7mL injection by Amgen Xgeva (denosumab; Amgen) has been approved for the treatment of unresectable giant cell tumor of the bone (GCTB) in adult and adolescent patients. The ...

Amgen, Inc. AMGN recently announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA to expand the label of its key drug, Xgeva. Xgeva is currently approved for the ...

A breast cancer diagnosis is devastating. To hear that it has metastasized takes that devastation to another level. Amgen’s “Moments that Matter” campaign for bone metastases drug, Xgeva (denosumab), ...

Amgen today announced the FDA plans to decide by April 26 on its application to expand the use of its bone treatment drug Xgeva to prevent or delay the spread of advanced prostate cancer. The drug is ...